Patient characteristics
. | NST group . | Auto-SCT group . | P . |
---|---|---|---|
No. | 9 | 26 | NA |
No. male/no. female | 7/2 | 21/5 | NS* |
Age, y (range) | 53 (40-63) | 51 (34-60) | NS† |
VH homology, % (range) | 100 (99.6-100) | 100 (98.3-100) | NS† |
FISH del 11q23 or del 17p13 (%) | 3/8 (38) | 8/23 (35) | NS* |
Lymphocyte doubling time less than 12 mos. (%) | 5/7 (71) | 14/17 (82) | NS* |
Binet stage B/C, no. (%) | 8 (89) | 17 (68) | NS* |
Time to ASCT, mos. (range) | 44 (8-129) | 12 (3-117) | .01† |
No. of previous regimens (range) | 4 (1-6) | 2 (1-4) | .009† |
. | NST group . | Auto-SCT group . | P . |
---|---|---|---|
No. | 9 | 26 | NA |
No. male/no. female | 7/2 | 21/5 | NS* |
Age, y (range) | 53 (40-63) | 51 (34-60) | NS† |
VH homology, % (range) | 100 (99.6-100) | 100 (98.3-100) | NS† |
FISH del 11q23 or del 17p13 (%) | 3/8 (38) | 8/23 (35) | NS* |
Lymphocyte doubling time less than 12 mos. (%) | 5/7 (71) | 14/17 (82) | NS* |
Binet stage B/C, no. (%) | 8 (89) | 17 (68) | NS* |
Time to ASCT, mos. (range) | 44 (8-129) | 12 (3-117) | .01† |
No. of previous regimens (range) | 4 (1-6) | 2 (1-4) | .009† |